Comparison between manufacturing sites shows differential adhesion, activation, and GPIbα expression of cryopreserved platelets

Six, Katrijn R.; Delabie, Willem; Devreese, Katrien; Johnson, Lacey; Marks, Denese C.; Dumont, Larry J.; Compernolle, Veerle; Feys, Hendrik B.

doi:10.1111/trf.14828

Cited by 29 publications

(63 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cryopreserved platelets are characterized by specific phenotypic changes . Following freezing and thawing, the platelets exhibited the features typical of cryo injury, including a loss of certain glycoproteins (GPIbα, GPIIb, GPVI), an increase in activation markers (phosphatidylserine and P‐selectin), the release of microparticles, and reduction in the clotting time.…”

Section: Discussionmentioning

confidence: 99%

“…Cryopreserved platelets are characterized by specific phenotypic changes. [8][9][10] Following freezing and thawing, the platelets exhibited the features typical of cryo injury, including a loss of certain glycoproteins (GPIbα, GPIIb, GPVI), an increase in activation markers (phosphatidylserine and P-selectin), the release of microparticles, and reduction in the clotting time. Importantly, the platelets frozen after collection or following room temperature storage for 5 or 6 days were almost indistinguishable in relation to these postthaw quality parameters.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Freezing expired platelets does not compromise in vitro quality: An opportunity to maximize inventory potential

et al. 2019

Self Cite

View full text Add to dashboard Cite

BACKGROUND AND OBJECTIVES Cryopreservation provides an option for long‐term storage of platelet concentrates. While platelets are usually frozen as soon as practical after collection (within 2 days), the ability to freeze units at a later stage of the shelf life may improve inventory management. As such, the aim of this study was to determine the impact of freezing platelets approaching expiry (Day 5/6). MATERIALS AND METHODS Two ABO‐matched buffy coat–derived platelets (30% plasma/70% platelet additive solution) were pooled and split to produce matched pairs (n = 8 pairs). Platelets were frozen on Day 1 after collection (cryopreserved platelets [CPPs]) or Day 5 or 6 (expired‐CPPs) at −80°C with 5% to 6% dimethyl sulfoxide. In vitro platelet quality was tested before freezing and after thawing and reconstitution in plasma. RESULTS The majority of prefreeze parameters were equivalent for all platelet units (Day 1 vs. Day 5 or 6). Expired‐CPPs had a higher mean postthaw platelet recovery (82 ± 4%) compared to CPPs (75 ± 4%; p = 0.0021). Cryopreservation resulted in a loss of surface glycoproteins (glycoprotein (GP) Ibα, GPIIb, GPVI), an increase in activation markers (phosphatidylserine and P‐selectin) and microparticle release, compared to unfrozen platelets. However, the cryopreservation‐induced changes were equivalent in CPPs and expired‐CPPs. Functionality was measured by thromboelastography and was similar between expired‐CPPs (R‐time: 5.3 ± 0.3) and CPPs (R‐time: 5.4 ± 0.5; p = 0.7094). CONCLUSION The phenotype and functional profile of platelets frozen at expiry were similar to platelets frozen 1 day following collection. These data suggest that expired platelets may represent a suitable starting material for cryopreservation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Freezing expired platelets does not compromise in vitro quality: An opportunity to maximize inventory potential

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Dutch and Australian military experience in Afghanistan with 1143 cryopreserved PLT units transfused into 349 patients suggested they were both safe and effective, although no comparisons with liquid‐stored PLTs or whole blood were made. Extensive preclinical assessments have found that, compared to liquid‐stored PLTs, cryopreserved PLTs have increased procoagulant activity, with alterations in membrane receptors and higher microparticle concentrations . A Phase I human study found lower 24‐hour PLT recovery in comparison to liquid‐stored PLTs, but with survival times exceeding US Food and Drug Administration requirements and with no associated adverse events .…”

mentioning

confidence: 99%

A randomized, controlled pilot clinical trial of cryopreserved platelets for perioperative surgical bleeding: the CLIP‐I trial (Editorial, p. 2759)

et al. 2019

Self Cite

View full text Add to dashboard Cite

BACKGROUND: Cryopreservation extends platelet (PLT) shelf life from 5 to 7 days to 2 to 4 years. However, only 73 patients have been transfused cryopreserved PLTs in published randomized controlled trials (RCTs), making safety data insufficient for regulatory approval. STUDY DESIGN AND METHODS: The Cryopreserved vs. Liquid Platelet (CLIP) study was a double-blind, pilot, multicenter RCT involving high-risk cardiothoracic surgical patients in four Australian hospitals. The objective was to test, as the primary outcome, the feasibility and safety of the protocol. Patients were allocated to study group by permuted block randomization, with patients and clinicians blinded by use of an opaque shroud placed over each study PLT unit. Up to 3 units of cryopreserved or liquid-stored PLTs were administered per patient. No other aspect of patient care was affected.Adverse events were actively sought. RESULTS:A total of 121 patients were randomized, of whom 23 received cryopreserved PLTs and 18 received liquid-stored PLTs.There were no differences in blood loss (median, 715 mL vs. 805 mL at 24 hr; difference between groups 90 mL [95% CI, -343.8 to 163.8 mL], p = 0.41), but the Bleeding Academic Research Consortium criterion for significant postoperative hemorrhage in cardiac surgery composite bleeding endpoint occurred in nearly twice as many patients in the liquidstored group (55.6% vs. 30.4%, p = 0.10). Red blood cell transfusion requirements were a median of 3 units in the cryopreserved group versus 4 units with liquid-stored PLTs (difference between groups, 1 unit [95% CI, -3.1 to 1.1 units]; p = 0.23). Patients in the cryopreserved group were more likely to be transfused fresh-frozen plasma (78.3% vs. 27.8%, p = 0.002) and received more study PLT units (median, 2 units vs. 1 unit; difference between groups, 1 unit [95% CI, -0.03 to 2.0 units]; p = 0.012).There were no between-group differences in potential harms including deep venous thrombosis, myocardial infarction, respiratory function, infection, and renal function. No patient had died at 28 days, and postoperative length of stay was similar in each group. CONCLUSION:In this pilot RCT, compared to liquid-stored PLTs, cryopreserved PLTs were associated with no evidence of harm. A definitive study testing safety and hemostatic effectiveness is warranted.A fter donation, platelets (PLTs) are stored at 20 to 24 C with agitation to prolong circulating time after transfusion. This limits their shelf life to 5 to 7 days 1 but despite this, PLTs cause 84% of transfusiontransmitted bacterial infections. 2 Short shelf life also leads to high levels of wastage: one-fourth to one-third of units are discarded due to expiry. 3,4 To limit wastage, PLTs are only kept routinely in larger hospitals where use is high and predictable. Bleeding patients in smaller hospitals are more likely to be denied this potentially lifesaving treatment. ABBREVIATIONS: BARC = Bleeding Academic Research Consortium; DVT = deep venous thrombosis; ICU = intensive care unit; IQR = interquartile range; OR ...

show abstract

“…These findings are currently being tested in a prospective clinical trial in cardiac surgery patients in Australia, and a similar study is in preparation in United States, funded by the US Department of Defense. Whether the Australian DMSO‐cryopreserved PLT preparations result in similar efficacy and/or safety profiles than the preparations in the United States and Europe remains unclear since their in vitro properties seem to be different …”

Section: Cryopreserved Pltsmentioning

confidence: 99%

“…Whether the Australian DMSO-cryopreserved PLT preparations result in similar efficacy and/or safety profiles than the preparations in the United States and Europe remains unclear since their in vitro properties seem to be different. 49…”

Section: Cryopreserved Pltsmentioning

confidence: 99%

Future of platelet formulations with improved clotting profile: a short review on human safety and efficacy data

Cancelas

2019

Transfusion

View full text Add to dashboard Cite

BACKGROUND Platelet (PLT) transfusion is a widely used therapy in treating or preventing bleeding and hemorrhage in patients with thrombocytopenia or trauma. Compared to the relative ease of PLT transfusion, current practice for PLT storage at room temperature (RT) for up to 5 to 7 days is inefficient, costly, wasteful, and relatively unsafe. STUDY DESIGN AND METHODS This study was a review of major advances in PLT derivative products with improved hemostatic potential and safety feature. RESULTS Recent progress in understanding the PLT activation and host clearance mechanisms has led to reassessments of current and new storage conditions that employ refrigeration and/or cryopreservation to overcome storage lesions and significantly extend shelf life of PLTs with reduced risk of pathogen contamination. DISCUSSION It is anticipated that future PLT preservation involving cold, frozen, and/or pathogen reduction strategies in proper PLT additive solutions will enable longer term and safer PLT storage.

show abstract

Comparison between manufacturing sites shows differential adhesion, activation, and GPIbα expression of cryopreserved platelets

Cited by 29 publications

References 37 publications

Freezing expired platelets does not compromise in vitro quality: An opportunity to maximize inventory potential

Freezing expired platelets does not compromise in vitro quality: An opportunity to maximize inventory potential

A randomized, controlled pilot clinical trial of cryopreserved platelets for perioperative surgical bleeding: the CLIP‐I trial (Editorial, p. 2759)

Future of platelet formulations with improved clotting profile: a short review on human safety and efficacy data

Contact Info

Product

Resources

About